您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Aflibercept
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Aflibercept
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
CAS NO:862111-32-8
包装与价格：
包装价格(元)
10mg电议
50mg电议
100mg电议

产品名称
VEGF Trap
VEGF-TRAPR1R2
VEGF-trapR1
产品介绍
Aflibercept (VEGF Trap) 是由 VEGFR1 和 VEGFR2 的 Ig 结构域与人 IgG1 的 Fc 域融合而成的可溶性诱饵 VEGFR。Aflibercept 抑制VEGF信号通过抑制 VEGF 参与调控的通路。Aflibercept 可以用于老年性黄斑变性 (AMD) 和心血管疾病的研究。
生物活性

Aflibercept (VEGF Trap) is a soluble decoyVEGFRconstructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of humanIgG1. Aflibercept inhibitsVEGFsignaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) andcardiovascular disease[1][2][3].

体外研究
(In Vitro)

Aflibercept (500 μg/mL; 24 h and 7 d) shows no toxicity on RPE cells, neither in MTT-assay nor in trypan blue exclusion assay[1].
Aflibercept (500 μg/mL; 24 h) shows a statistically significant effect on wound healing compared with control in the confluent RPE cell layer with three wounds[1].
Aflibercept (500 μg/mL; 7 d) displays a significantly diminished phagocytosis of opsonised latex beads compared to untreated control[1].
Aflibercept (1 and 10 μg/mL; 10 h) inhibits VEGF signaling by reducing VEGF-regulated processes, such as permeability and angiogenesis[2].

体内研究
(In Vivo)

Aflibercept (10 mg/kg; 3 h post-middle cerebral artery occlusion (MCAO)) reduces stroke-induced VEGF-A and VEGFR2 expression, and brain edema, and BBB disruption and improves poststroke survival in obese mice[2].
Aflibercept (18.2 mg/kg and 36.4 mg/kg; i.v. once) affects BP, ROS and eNOS production in mice[3].

Animal Model:Male C57BL/6 mice[3]
Dosage:18.2 mg/kg and 36.4 mg/kg
Administration:Intravenous injection; 18.2 mg/kg and 36.4 mg/kg once
Result:Rapidly and dose-dependently elevated BP in mice and markedly impaired endothelial-dependent relaxation (EDR) and resulted in NADPH oxidases 1 (NOX1)- and NADPH oxidases 4 (NOX4)-mediated generation of ROS, decreased the activation of protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) concurrently with a reduction in nitric oxide (NO) production and elevation of ET-1 levels in mouse aortas.
性状

Liquid

CAS 号

862111-32-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Pure form-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month